Clinical Scorecard: Musings from The Power List: Miguel Forte
At a Glance
| Category | Detail |
|---|---|
| Condition | Cell and Gene Therapy |
| Key Mechanisms | Manufacturing capacity, clinical delivery, reimbursement models |
| Target Population | Patients with unmet medical needs |
| Care Setting | Clinical and regulatory environments |
Key Highlights
- Establishment of ISCT's clinical pillar with a Chief Medical Officer
- Challenges in patient access due to manufacturing and reimbursement constraints
- Progress in allogeneic cell therapies derived from iPSCs
- Need for new business models to expand patient access
- Importance of faster clinical trial approvals for evidence generation
Guideline-Based Recommendations
Diagnosis
Management
- Strengthen the value proposition and clinical data to attract investment
- Consider operational changes for faster clinical trial approvals
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with unmet medical needs in cell and gene therapy
Potential for long-lasting, curative outcomes with new therapies
Clinical Best Practices
- Adopt pragmatic approaches in Health Technology Assessment decisions
- Support flexible reimbursement models reflecting long-term therapy value
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
